On November 17, 2021 BioVaxys Technology Corp. (CSE: BIOV, FRA:5LB,OTCQB:BVAXF) ("BioVaxys" or "Company"), a clinical-stage immunotherapy company, reported that Company Co-Founder and Chief Medical Officer David Berd, MD, will present at the World Vaccine & Immunotherapy Congress West Coast 2021 taking place November 30-December 2, 2021 in San Diego (Press release, BioVaxys Technology, NOV 17, 2021, https://biovaxys.com/2021/11/17/biovaxys-co-founder-and-chief-medical-officer-david-berd-md-to-present-at-world-vaccine-immunotherapy-congress-west-coast-2021/ [SID1234595730]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Berd will discuss the role of immunotherapeutic vaccines in cancer, the potential of haptenized autologous tumor cell vaccines for treating a range of cancer types, and BioVaxys’ advancement of haptenized viral antigens as a platform for addressing SARS-CoV-2, SARS-CoV-1, and other sarbecoviruses.

Details of the presentation are as follows:

Title: Haptenized Vaccines for Viral Diseases & Cancer

When: December 1, 2021 @ 17:10
Where: Lowes Coronado Hotel, San Diego, CA

"BioVaxys is honored to be invited to speak at the World Vaccine & Immunotherapy Congress alongside a prestigious group of vaccine and immunology experts. We look forward to sharing how we are leveraging our haptenized protein platform to create autologous cancer immunotherapies synergistic with checkpoint inhibitors, as well as protein-based vaccines for infectious disease," said Dr. Berd.

A medical oncologist, Dr. Berd has a life-long record of clinical research in medical oncology and cancer immunotherapy. For more than 20 years, he was a professor of medicine at Thomas Jefferson University, where he conducted clinical research on melanoma vaccines. Over the course of his career, Dr. Berd has published more than 85 original papers in numerous medical journals in addition to myriad editorials, reviews, and abstracts. He has 10 issued cancer vaccines patents.

On November 17, 2021 Boundless Bio, a next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) in aggressive cancers, reported that the Chief Executive Officer of Boundless Bio, Zachary Hornby, will present at the Piper Sandler 33rd Annual Virtual Healthcare Conference and the Evercore ISI 4th Annual HealthCONx Conference (Press release, Boundless Bio, NOV 17, 2021, View Source [SID1234595746]). Presentation details are as follows:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Piper Sandler 33rd Annual Virtual Healthcare Conference
Date: Pre-recorded presentation accessible on Monday, November 22, 2021
Time: 10:00 a.m. ET / 7:00 a.m. PST

Evercore ISI 4th Annual HealthCONx Conference
Date: Live presentation on Wednesday, December 1, 2021
Time: 1:50 p.m. ET / 10:50 a.m. PST

On November 17, 2021 Eli Lilly and Company (NYSE: LLY) reported that it will participate in the fourth annual Evercore ISI HealthCONx Conference on Tuesday, Nov. 30, 2021. Daniel Skovronsky, M.D., Ph.D., Lilly’s chief scientific and medical officer, and president of Lilly Research Laboratories, will participate in a fireside chat at 12:10 p.m., Eastern time (Press release, Eli Lilly, NOV 17, 2021, https://investor.lilly.com/news-releases/news-release-details/lilly-participate-fourth-annual-evercore-isi-healthconx [SID1234595731]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast will be available on the "Webcasts & Presentations" section of Lilly’s Investor website at View Source A replay of the presentation will be available on this same website for approximately 90 days.

On November 17, 2021 Abintus Bio, Inc. (Abintus), a company pioneering first-in-class, off-the-shelf medicines that reprogram cells directly in vivo, reported that it has entered into an agreement with Memorial Sloan Kettering Cancer Center for the use of its next generation signaling technology ("1XX") in Abintus’ In Vivo CAR-X products (Press release, Abintus Bio, NOV 17, 2021, View Source [SID1234595747]). These products have the potential to overcome the challenges of ex vivo CAR technologies and dramatically improve outcomes and access for patients with hematologic malignancies and solid tumors.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Having the opportunity to directly reprogram the innate and adaptive immune cell subsets with retroviral vectors, while also extending CAR immune cell function and persistence with 1XX, is an advantage for Abintus’ approach and has the potential to establish potent anti-tumor immune responses," said Michel Sadelain, M.D., Ph.D., MSK’s Director of the Center for Cell Engineering and inventor of 1XX signaling technology. "I look forward to our continued support as these products advance towards clinical investigation."

1XX signaling technology is designed to improve the persistence of chimeric antigen receptor (CAR)-engineered cells by sustaining cellular effector functions without exhaustion. To date, 1XX CARs have demonstrated superior preclinical activity compared to conventional CAR technologies in certain hematologic and solid tumors including B-cell malignancies, mesothelioma, ovarian cancer, and breast cancer. 1XX CARs are currently under clinical evaluation in multiple cancers. In Vivo CAR-X products are designed to simultaneously target both adaptive and innate immune effector cells, including active T cells and Natural Killer (NK) cells, to produce a potent and durable immune response against hematologic malignancies and solid tumors, and improve patient outcomes and access.

"For in vivo reprogramming to have a profound impact, it will require safe and well tolerated gene delivery and functional expression as well as manufacturing that can scale to meet the patient need," said Malcolm Brenner, M.D., Professor at Baylor College of Medicine, Director of the Center for Cell and Gene Therapy at the Baylor College of Medicine, Texas Children’s Hospital, and Houston Methodist Hospital and advisor. "Abintus’ retroviral technology is an ideal platform for in vivo reprogramming because it addresses these key criteria, and has a compelling precedent for safety, tolerability and proof of principle in patients with intravenous administration. Adding 1XX signaling technology further strengthens Abintus’ differentiated approach."

Abintus’ initial products targeting hematologic and solid tumors are poised to enter clinical evaluation as early as 2023.

"One of the most exciting and impactful areas of research is the reprogramming of cells directly inside a patient. Inspired by nature, Abintus’ in vivo reprogramming technology is designed to empower patients with a diverse team of living drugs that can launch a coordinated attack against their cancer," said Nicholas A. Boyle, Ph.D., CEO and cofounder of Abintus. "The insights gained from our historical observations with in vivo reprogramming in patients, combined with 1XX technology and our commercial-ready manufacturing process, positions our company with the knowhow, technology and experience to make in vivo genetic medicines a reality for patients."

On November 17, 2021 BeiGene reported that was approved to stage a $3 billion IPO on Shanghai’s STAR Exchange, the company’s third listing (Press release, BeiGene, NOV 17, 2021, View Source [SID1234595836]). Previously, the company completed an $182 million IPO on NASDAQ in 2016 and a $900 million Hong Kong IPO in 2018. It will be the first biopharma to list on the three exchanges. The China Securities Regulatory Commission (CSRC) signed off on the IPO this week, the last requirement for the process. Founded in 2010, BeiGene focuses on developing molecularly targeted and immuno-oncology drug candidates.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!